These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33740433)

  • 1. Phenotypic screening with target identification and validation in the discovery and development of E3 ligase modulators.
    Ege N; Bouguenina H; Tatari M; Chopra R
    Cell Chem Biol; 2021 Mar; 28(3):283-299. PubMed ID: 33740433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs.
    Heim C; Maiwald S; Steinebach C; Collins MK; Strope J; Chau CH; Figg WD; Gütschow M; Hartmann MD
    Biochem Biophys Res Commun; 2021 Jan; 534():67-72. PubMed ID: 33310190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Discovery of the target for immunomodulatory drugs (IMiDs)].
    Ito T; Ando H; Handa H
    Rinsho Ketsueki; 2016 May; 57(5):556-62. PubMed ID: 27263779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs.
    Ito T; Handa H
    Int J Hematol; 2016 Sep; 104(3):293-9. PubMed ID: 27460676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
    Petzold G; Fischer ES; Thomä NH
    Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
    Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
    J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homo-PROTACs for the Chemical Knockdown of Cereblon.
    Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
    ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
    Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
    FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
    Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
    Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders.
    Yamamoto J; Ito T; Yamaguchi Y; Handa H
    Chem Soc Rev; 2022 Aug; 51(15):6234-6250. PubMed ID: 35796627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
    Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
    J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRL4
    Barankiewicz J; Salomon-Perzyński A; Misiewicz-Krzemińska I; Lech-Marańda E
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators.
    Liu L; Sun R; Liu H; Ren C; Zhou Y; Qiu X; Kong Y; Jiang B; Yang X
    Eur J Med Chem; 2023 Feb; 247():115016. PubMed ID: 36577219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potential novel CRBN modulators by virtual screening and bioassay.
    Xiong F; Kong L; Chen L; Xue M; Cao F; Zhang S; Li H; Yan H; Li Y; Zuo Z
    Eur J Med Chem; 2022 Jun; 236():114355. PubMed ID: 35413617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interacting domains in cereblon differentially modulate the immunomodulatory drug-mediated ubiquitination and degradation of its binding partners.
    Tao J; Yang J; Xu G
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):443-449. PubMed ID: 30458989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide.
    Furihata H; Yamanaka S; Honda T; Miyauchi Y; Asano A; Shibata N; Tanokura M; Sawasaki T; Miyakawa T
    Nat Commun; 2020 Sep; 11(1):4578. PubMed ID: 32929090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues.
    Yamanaka S; Horiuchi Y; Matsuoka S; Kido K; Nishino K; Maeno M; Shibata N; Kosako H; Sawasaki T
    Nat Commun; 2022 Jan; 13(1):183. PubMed ID: 35013300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical evaluation of the approaches to targeted protein degradation for drug discovery.
    Chopra R; Sadok A; Collins I
    Drug Discov Today Technol; 2019 Apr; 31():5-13. PubMed ID: 31200859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.
    Cheng J; Guo J; North BJ; Tao K; Zhou P; Wei W
    Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):138-159. PubMed ID: 30602127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
    Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
    Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.